ÂÜÀòÂÒÂ×

Ken Brameld is a seasoned professional in the field of chemistry and drug discovery, currently serving on the Scientific Advisory Board at Drug Hunter, and holding the position of Fellow and Head of Discovery at Alumis since September 2021. With a strong background in small molecule drug discovery and computational chemistry, Ken has been the Principal at Drug by Design since April 2010 and has served on multiple scientific advisory boards, including Iambic Therapeutics, OpenBench, and Frontier Medicines. A former Senior Vice President and Head of Research at Principia Biopharma, Ken's career also includes significant roles at Roche Palo Alto as Principal Scientist and Group Leader. Ken earned a Ph.D. in Chemistry from Caltech and a BS in Chemistry from the University of Washington.